1. Introduction {#s0005}
===============

Colorectal cancer (CRC) is the second most common cause of cancer related mortalities in Saudi Arabia, and the incidence is rising since past decade. Accumulated evidence in the past three decades suggests WNT signaling pathway genes to be mutated in very high proportion of sporadic colorectal tumors. Wnt ligands are a family of 19 glycoproteins which have a key role in early development and tissue homeostasis. Any changes in WNT signaling genes may cause disease including colorectal cancer ([@b0055], [@b0065]). The possible role of WNT genes in cancer has been reported few decades ago in mouse models. Variation in expression levels of WNT1 lead to tumor formation in transgenic mice ([@b0060]). Further studies reported that WNT genes promoted stabilization of β-catenin and β-catenin dependent transcription. Axin, APC and GSK3β forms β-catenin destruction complex. Canonical WNT pathway activity is dependent on this complex, which eradicates newly formed β-catenin protein through the ubiquitin--proteasome pathway in the off-state when WNT ligands are not bound to its receptors frizzled and LRP5/6 ([@b0025]). In the on-state, WNT ligands bind to its receptors resulting in cytoplasmic accumulation of β-catenin which than translocates into the nucleus leading to formation of a complex with TCF/LEF family of transcription factors. This complex formation drives transcriptional activation of genes involved in cell proliferation such as c-Myc and Cyclin D ([@b0035]).

The high rate of WNT pathway genes mutations in various cancers emphasizes the significance of WNT/β-catenin signaling pathway in cancer progression. Apart from APC that has been reported to play crucial role in colorectal cancer progression, The Cancer Genome Atlas Network has reported the involvement of several other WNT pathway genes ([@b0015]). Although mutations in genes such as FZD4, LRP5 and LRP6 that obstruct WNT signaling have been recognized in other diseases, similar WNT-pathway inactivating mutations have not been identified in cancer ([@b0015]). Most of the WNT pathway gene mutations reported in cancer are found to result in hyperactivation of WNT pathway. β-catenin missense and other mutations are very common in hepatocellular carcinoma and ovarian cancer, whereas deletions and truncation mutations in *AXIN1* are commonly observed in hepatocellular carcinoma and colorectal cancers ([@b0045], [@b0015]). Thus, in light of the previous reports that provide compelling evidence of the involvement of Wnt signaling pathway in the progression of colorectal cancer, we in the present study evaluated the association of SNPs in WNT signaling pathway genes with susceptibility to colorectal cancer in Saudi population. We investigated 13 germline polymorphisms in 8 genes involved in the Wnt signaling pathway to evaluate their risk association in patients with colorectal cancer.

2. Materials and methods {#s0010}
========================

2.1. Study population {#s0015}
---------------------

This study was approved by ethical review committee of King Khalid University Hospital, Riyadh, Saudi Arabia and written informed consent was obtained from all participants. The samples comprised of 122 colorectal cancer patients (age 18--82 years, mean age 57 years). Additionally, 110 gender and age matched non-cancer samples were recruited as controls in the present study. 5 ml blood was collected from patients and healthy individuals. Histology and TNM staging were analyzed to verify the diagnosis. Demographic information for the colorectal cancer and control subjects are presented in [Table 1](#t0005){ref-type="table"}.Table 1Demographic characteristics of CRC patients and control subjects.CharacteristicsCaseControlSamples122110Age \<576248 \>576062Gender Male7457 Female4853

2.2. Genotyping {#s0020}
---------------

The DNA was isolated from colorectal cancer patients and control blood samples using DNA extraction kit (Qiagen, Valencia, CA) according to the manual of manufacturer. A total of 13 SNPs located in eight genes involved in WNT signaling pathway were selected based on previous literature and genotyped using predesigned TaqMan assays using ABI 7500 real-time PCR machine (Applied Biosystems, USA) as previously described ([@b0010]). The SNPs selected were located in SFRP3 (rs7775), APC (rs454886, rs459552), LRP6 (rs2075241, rs2284396), DKK4 (rs3763511), AXIN2 (rs3923086, rs3923087, rs4791171), β-catenin (rs4135385, rs13072632), DKK3 (rs6485350) and TCF4 (rs12255372) genes respectively. Around 10% of the samples were randomly used to reconfirm the results.

2.3. Statistical analysis {#s0025}
-------------------------

The Hardy--Weinberg equilibrium was assessed using χ2 test for controls and cases. Pearson's goodness-of-fit chi-square (χ2) values, odds ratios (OR), 95% confidence intervals (CI), and p values were calculated using SPSS *ver* 22 to find out the association between genotypes of all the SNPs with colorectal cancer risk as described by [@b0005].

3. Results {#s0030}
==========

The demographic characteristics of selected samples are shown in [Table 1](#t0005){ref-type="table"}.

3.1. Association of SNPs with colorectal cancer risk {#s0035}
----------------------------------------------------

The study group comprised of 122 patients with histopathologically confirmed colorectal cancer and 110 age and gender matched cancer-free controls ([Table 1](#t0005){ref-type="table"}). To evaluate the role of WNT pathway genes in colorectal carcinogenesis, we examined 13 SNPs in eight genes of WNT signaling pathway ([Table 2](#t0010){ref-type="table"}).Table 2Genotype frequencies of WNT pathway gene polymorphism in colorectal cancer cases and controls.GeneSNPVariantCases (Freq)ControlsORCIχ^2^ ValueP-ValueSFRP3rs7775Arg/Arg96 (0.79)77(0.70)RefArg/Gly24 (0.20)30(0.27)0.6420.347--1.1872.020.15570Gly/Gly2 (0.01)3 (0.02)0.5350.087--3.2810.470.49239Arg216(0.89)184(0.83)RefGly28 (0.11)36 (0.16)0.6630.389--1.1272.320.12732  APCrs454886TT53 (0.45)53(0.49)RefTC54 (0.46)44 (0.40)1.2270.707--2.1290.530.46598CC10 (0.9)13 (0.11)0.7690.310--1.9070.320.57058T160(0.68)150(0.69)RefC74 (0.32)70 (0.31)0.9910.667--1.4720.000.96455  APCrs459552Val/Val88 (0.72)72 (0.65)RefVal/Asp30 (0.25)35 (0.32)0.7010.393--1.2511.450.22848Asp/Asp4 (0.33)3 (0.02)1.0910.236--5.0330.010.91117Val206(0.84)179(0.81)RefAsp38 (0.16)41 (0.19)0.8050.496--1.3080.770.38080  LRP6rs2075241GG92 (0.75)76 (0.70)RefGC24 (0.19)31 (0.29)0.6400.346--1.1812.050.15172CC6 (0.04)1 (0.009)4.9570.584--42.0732.610.10600G208(0.85)183(0.85)RefC36 (0.14)33 (0.15)0.9600.575--1.6020.020.87526  LRP6rs2284396TT64 (0.53)50 (0.46)RefTC43 (0.35)40 (0.37)0.8400.476--1.4820.360.54661CC14 (0.11)19 (0.17)0.5760.263--1.2601.930.16442T171(0.70)140(0.64)RefC71 (0.3)78 (0.36)0.7450.504--1.1022.170.14049  DKK4rs3763511CC87 (0.70)80 (0.73)RefCT32 (0.26)29 (0.26)1.0150.564--1.8250.000.96124TT4 (0.03)1 (0.009)3.6780.403--33.6041.520.21805C206(0.83)189(0.86)RefT40 (0.16)31 (0.14)1.1840.712--1.9690.420.51536  AXIN2rs3923086TT48 (0.39)41 (0.37)RefTG52 (0.42)50 (0.45)0.8880.503--1.5700.170.68364GG21 (0.17)19 (0.17)0.9440.447--1.9940.020.88007T148(0.61)132(0.60)RefG94 (0.38)88 (0.40)0.9530.656--1.3840.060.79934  AXIN2rs3923087AA35 (0.28)37 (0.33)RefAG56 (0.45)50 (0.45)1.1840.650--2.1560.310.58049GG32 (0.26)23 (0.20)1.4710.725--2.9841.150.28440A126(0.51)124(0.56)RefG120(0.49)96 (0.44)1.2300.854--1.7731.240.26627  AXIN2rs4791171AA40 (0.32)38 (0.34)RefAG55 (0.45)48 (0.43)1.0890.604--1.9620.080.77771GG27 (0.22)24 (0.22)1.0690.527--2.1670.030.85370A135(0.55)124(0.56)RefG109(0.44)96 (0.44)1.0430.723--1.5050.050.82250  β-cateninrs4135385AA89 (0.74)74 (0.67)RefAG31 (0.26)32 (0.30)0.8050.450--1.4420.530.46618GG0 (0.0)4 (0.04)0.0920.005--1.7464.68**0.03059**A209(0.87)180(0.81)RefG31 (0.13)40 (0.18)0.6670.401--1.1112.440.11844  β-cateninrs13072632CC51 (0.42)46 (0.42)RefCT47 (0.39)51 (0.46)0.8310.474--1.4580.420.51900TT23 (0.19)13 (0.11)1.5960.725--3.5101.360.24335C149(0.61)143(0.65)RefT93 (0.38)77 (0.35)1.1590.793--1.6940.580.44519  DKK3rs6485350AA46 (0.39)36 (0.33)RefAG56 (0.47)50 (0.45)0.8770.491--1.5640.200.65563GG17 (0.14)24 (0.22)0.5540.259--1.1842.340.12586A148(0.62)122(0.55)RefG90 (0.37)98 (0.44)0.7570.521--1.1002.140.14350  TCF4rs12255372GG47 (0.40)49 (0.44)RefGT56 (0.47)46 (0.42)1.2690.726--2.2190.700.40279TT17 (0.14)15 (0.14)1.1820.530--2.6330.170.68309G150(0.62)144(0.65)RefT90 (0.37)76 (0.34)1.1370.776--1.6650.430.50982

Ancestral allele was selected based on NCBI SNP database and used as a reference to calculate the odds to check the association of genotypes and alleles with colorectal cancer. The overall genotype frequencies of the analyzed SNPs and the odds ratio and significance are presented in [Table 2](#t0010){ref-type="table"}. The allelic frequencies of all tested SNPs were in limits of Hardy--Weinberg equilibrium. The homozygous GG genotype of SNP rs4135385 in the β-catenin gene showed significant protective association (OR: 0.092, p = 0.03) ([Table 2](#t0010){ref-type="table"}). We did not detect any statistically significant association with the risk of developing colorectal cancer for the other twelve SNPs examined in the overall study population ([Table 2](#t0010){ref-type="table"}). However, when the samples were segregated based on gender and age at disease diagnosis, SNP rs7775 in SFRP3 gene showed significant protective association in female patients with minor allele Gly (OR 0.397, p = 0.02) as well as with heterozygous Arg/Gly genotype (OR 0.408, p = 0.04 ([Table 3](#t0015){ref-type="table"}). None of the evaluated SNPs showed significant protective or risk association with colorectal cancer in males ([Table 4](#t0020){ref-type="table"}) as well as in patients whose age at the time of disease diagnosis was below 57 years ([Table 5](#t0025){ref-type="table"}). Interestingly, the CC genotype of LRP6 gene SNP rs2284396 showed significant protective association with colorectal cancer in patients who were above 57 years of age at the time of disease diagnosis (OR: 0.250, p = 0.021). In the allelic model as well similar protection against colorectal cancer was observed with the C allele of LRP6 SNP rs2284396 in individuals who were above 57 years of age (OR 0.561, p = 0.03) ([Table 6](#t0030){ref-type="table"}).Table 3Distribution of WNT pathway gene SNPs genotype and allele frequencies in colorectal cancer cases and control population based on gender (female).SNPVariantCases (Freq)ControlsORCIχ^2^ ValueP-Valuers7775Arg/Arg38 (0.79)31 (0.59)RefArg/Gly10 (0.20)20 (0.38)0.4080.167--0.9983.96**0.04670**Gly/Gly0 (0.0)2 (0.03)0.1640.008--3.5342.370.12370Arg86 (0.90)82 (0.80)RefGly10 (0.10)24 (0.20)0.3970.179--0.8825.38**0.02039**  rs454886TT24 (0.55)26 (0.49)RefCT17 (0.40)21 ()0.400.8770.376--2.0450.090.76116CC2 (0.05)6 (0.11)0.3610.066--1.9641.480.22454T65 (0.76)73 (0.69)RefC21 (0.24)33 (0.31)0.7150.376--1.3571.060.30354  rs459552Val/Val35 (0.73)35 (0.67)RefVal/Asp9 (0.19)17 (0.32)0.5290.208--1.3471.810.17882Asp/Asp4 (0.08)1 (0.01)4.0000.425--37.6051.680.19457Val79 (0.82)87 (0.82)RefAsp17 (0.17)19 (0.18)0.9850.479--2.0280.96802  rs2075241GG41(0.85)39 (0.73)RefGC5 (0.10)13 (0.25)0.3660.119--1.1223.250.07141CC2 (0.04)1 (0.02)1.9020.166--21.8300.280.59983G87(0.91)91(0.86)RefC9 (0.09)15 (0.14)0.6280.261--1.5091.100.29481  rs2284396TT26 (0.55)24 (0.45)RefTC13 (0.28)21 (0.40)0.5710.235--1.3871.540.21437CC8 (0.17)8 (0.15)0.9230.299--2.8460.020.88919T65 (0.70)69 (0.65)RefC29 (0.30)37 (0.35)0.8320.460--1.5050.370.54277  rs3763511CC32 (0.66)39 (0.74)RefCT14 (0.30)14 (0.26)1.2190.508--2.9260.200.65783TT2 (0.04)0 (0.0)6.0770.282--131.1232.360.12458C78 (0.81)92 (0.87)RefT18 (0.19)14 (0.13)1.5160.709--3.2451.160.28131  rs3923086TT19 (0.40)19 (036)RefTG21 (0.44)24 (0.45)0.8750.369--2.0770.090.76204GG8 (0.16)10 (0.19)0.8000.259--2.4680.150.69759T59 (0.61)62 (0.59)RefG37 (0.39)44 (0.41)0.8840.503--1.5530.180.66735rs3923087AA14 (0.29)18 (0.34)RefAG21 (0.43)23 (0.43)1.1740.470--2.9320.120.73126GG13 (0.27)12 (0.23)1.3930.487--3.9820.380.53591A49 (0.51)59 (0.56)RefG47 (0.49)47 (0.44)1.2040.692--2.0950.430.51104  rs4791171AA15 (0.32)19 (0.36)RefAG26 (0.55)19 (0.36)1.7330.705--4.2591.450.22891GG6 (0.28)15 (0.28)0.5070.158--1.6231.330.24894A56 (0.60)57 (0.54)RefG38 (0.40)49 (0.46)0.7890.450--1.3840.680.40886  rs4135385AA34 (0.74)34 (0.64)RefAG12 (0.26)16 (0.30)0.7500.309--1.8200.410.52428GG0 (0.0)3 (0.06)0.1430.007--2.8712.880.08978A80 (0.87)84 (0.79)RefG12 (0.13)22 (0.21)0.5730.266--1.2332.060.15130  rs13072632CC22 (0.46)22 (0.42)RefCT16 (0.33)25 (0.47)0.6400.270--1.5151.030.30916TT10 (0.21)6 (0.11)1.6670.516--5.3810.740.39075C60 (0.63)69 (0.65)RefT36 (0.37)37 (0.35)1.1190.630--1.9880.150.70150  rs6485350AA19 (0.43)16 (0.30)RefAG19 (0.43)29 (0.55)0.5520.229--1.3321.760.18429GG6 (0.14)8 (0.15)0.6320.181--2.2050.520.46971A57 (0.65)61 (0.58)RefG31 (0.35)45 (0.42)0.7370.412--1.3201.050.30470  rs12255372GG20 (0.42)22 (0.42)RefGT18 (0.37)25 (0.47)0.7920.336--1.8650.290.59342TT10 (0.21)6 (0.11)1.8330.564--5.9631.030.31075G58 (0.60)69 (0.65)RefT38 (0.40)37 (0.35)1.2220.690--2.1640.470.49198Table 4Distribution of WNT pathway gene SNPs genotype and allele frequencies in colorectal cancer cases and control population based on gender (male).SNPVariantCases (Freq)ControlsORCIχ^2^ ValueP-Valuers7775Arg/Arg58 (0.78)46(0.81)RefArg/Gly14 (0.19)10(0.18)1.1100.452--2.7280.050.81946Gly/Gly2 (0.03)1(0.01)1.5860.139--18.0440.140.70770Arg130(0.88)102(0.89)RefGly18(0.12)12(0.11)1.1770.542--2.5550.170.68015  rs454886TT29(0.39)27(0.47)RefCT37(0.50)23(0.40)1.4980.716--3.1351.150.28289CC8(0.11)7(0.13)1.0640.340--3.3330.010.91514T95(0.64)77(0.68)RefC53(0.36)37(0.32)1.1610.693--1.9460.320.57079  rs459552Val/Val53(0.72)37(0.65)RefVal/Asp21(0.28)18(0.32)0.8140.382--1.7360.280.59481Asp/Asp0(0.0)2(0.03)0.1400.007--3.0052.780.09555Val127(0.86)92(0.81)RefAsp21(0.14)22(0.19)0.6910.359--1.3321.230.26833  rs2075241GG51(0.69)37(0.67)RefGC19(0.26)18(0.33)0.7660.354--1.6560.460.49719CC4(0.05)0(0.0)6.5530.342--125.4452.810.09349G121(0.82)92(0.84)RefC27(0.18)18(0.16)1.1400.592--2.1960.150.69397  rs2284396TT38(0.52)26(0.46)RefTC30(0.40)19(0.34)1.0800.505--2.3120.040.84224CC6(0.08)11(0.20)0.3730.123--1.1363.140.07644T106(0.72)71(0.63)RefC42(0.28)41(0.37)0.6860.406--1.1601.990.15872  rs3763511CC55(0.73)41(0.72)RefCT18(0.24)15(0.26)0.8950.404--1.9820.080.78364TT2(0.03)1(0.02)1.4910.131--17.0080.100.74629C128(0.85)97(0.85)RefT22(0.15)17(0.15)0.9810.494--1.9470.000.95557  rs3923086TT29(0.40)22(0.39)RefTG31(0.42)26(0.45)0.9050.423--1.9360.070.79595GG13(0.18)9(0.16)1.0960.397--3.0220.030.85972T89(0.61)70(0.61)RefG57(0.39)44(0.39)1.0190.616--1.6840.010.94182  rs3923087AA21(0.28)19(0.33)RefAG35(0.47)27(0.47)1.1730.528--2.6060.150.69536GG19(0.25)11(0.20)1.5630.594--4.1130.820.36473A77(0.51)65(0.57)RefG73(0.49)49(0.43)1.2580.771--2.0530.840.35884  rs4791171AA25(0.33)19(0.33)RefAG29(0.39)29(0.51)0.7600.346--1.6710.470.49444GG21(0.28)9(0.16)1.7730.664--4.7371.320.25099A79(0.53)67(0.59)RefG71(0.47)47(0.41)1.2810.784--2.0950.980.32301  rs4135385AA55(0.74)40(0.70)RefAG19(0.26)16(0.28)0.8640.396--1.8840.140.71243GG0(0.0)1(0.02)0.2430.010--6.1251.360.24430A129(0.87)96(0.84)RefG19(0.13)18(0.16)0.7860.391--1.5770.460.49641  rs13072632CC29(0.40)24(0.42)RefCT31(0.42)25(0.44)1.0260.482--2.1830.000.94646TT13(0.18)8(0.14)1.3450.478--3.7800.320.57366C89(0.61)73(0.64)RefT57(0.39)41(0.36)1.1400.687--1.8930.260.61154  rs6485350AA27(0.36)20(0.35)RefAG37(0.49)21(0.37)1.3050.593--2.8700.440.50745GG11(0.14)16(0.28)0.5090.195--1.3311.920.16632A91(0.60)61(0.54)RefG59(0.40)53(0.46)0.7460.456--1.2211.360.24377  rs12255372GG27(0.37)27(0.47)RefGT38(0.53)21(0.37)1.8100.851--3.8462.390.12172TT7(0.10)9(0.16)0.7780.253--2.3900.190.66042G92(0.64)75(0.66)RefT52(0.36)39(0.34)1.0870.649--1.8190.100.75103Table 5Distribution of WNT pathway gene SNPs genotype and allele frequencies in colorectal cancer cases and control population based on age (\<57).SNPVariantCases (Freq)ControlsORCIχ^2^ ValueP-Valuers7775Arg/Arg48(0.78)37(0.77)RefArg/Gly13(0.21)9(0.19)1.1130.430--2.8850.050.82488Gly/Gly1(0.01)2(0.41)0.3850.034--4.4150.630.42786Arg109(0.88)83(0.86)RefGly15(0.12)13(0.14)0.8790.396--1.9470.100.74980  rs454886TT25(0.44)24(0.50)RefCT25(0.44)20(0.42)1.2000.533--2.7030.190.65979CC7(0.12)4(0.08)T75(0.66)68(0.71)RefC39(0.34)28(0.29)1.2630.703--2.2690.610.43469  rs459552Val/Val43(0.68)31(0.65)RefVal/Asp17(0.27)14(0.29)0.8750.376--2.0370.100.75747Asp/Asp3(0.05)3(0.06)0.7210.136--3.8130.150.69920Val103(0.82)76(0.79)RefAsp23(0.18)20(0.21)0.8490.435--1.6560.230.62996  rs2075241GG48(0.76)37(0.77)RefGC12(0.19)10(0.21)0.9250.360--2.3740.030.87118CC3(0.04)1(0.02)2.3120.231--23.1450.540.46406G108(0.86)84(0.87)RefC18(0.14)12(0.13)1.1670.533--2.5560.150.69982  rs2284396TT32(0.52)24(0.50)RefTC19(0.31)18(0.37)0.7920.344--1.8230.300.58279CC10(0.16)6(0.13)1.2500.399--3.9170.150.70148T83(0.68)66(0.69)RefC39(0.32)30(0.31)1.0340.581--1.8380.010.91001  rs3763511CC45(0.71)34(0.71)RefCT17(0.27)13(0.27)0.9880.423--2.3080.000.97781TT1(0.01)1(0.02)0.7560.046--12.5170.040.84438C107(0.85)81(0.84)RefT19(0.15)15(0.16)0.9590.459--2.0020.010.91095  rs3923086TT27(0.13)18(0.37)RefTG22(0.35)21(0.44)0.6980.300--1.6250.700.40417GG14(0.22)9(0.19)1.0370.371--2.8990.000.94472T76(0.60)57(0.60)RefG50(0.40)39(0.40)0.9620.559--1.6530.020.88712  rs3923087AA15(0.24)16(0.33)RefAG32(0.51)24(0.50)1.4220.589--3.4330.620.43258GG16(0.25)8(0.17)2.1330.708--6.4281.840.17521A62(0.49)56(0.58)RefG64(0.51)40(0.42)1.4450.846--2.4681.820.17698  rs4791171AA22(0.35)17(0.35)RefAG27(0.44)23(0.48)0.9070.391--2.1070.050.82058GG13(0.21)8(0.17)1.2560.424--3.7140.170.68052A71(0.57)57(0.60)RefG53(0.43)39(0.40)1.0910.635--1.8740.100.75223  rs4135385AA42(0.70)33(0.69)RefAG18(0.30)13(0.27)1.0880.467--2.5370.040.84532GG0(0.0)2(0.04)0.1580.007--3.3962.460.11648A102(0.85)79(0.82)RefG18(0.15)17(0.18)0.8200.397--1.6930.290.59143  rs13072632CC23(0.37)16(0.33)RefCT27(0.44)25(0.52)0.7510.325--1.7380.450.50348TT12(0.19)7(0.16)1.1930.385--3.6900.090.75985C73(0.59)57(0.59)RefT51(0.41)39(0.41)1.0210.594--1.7560.010.93989  rs6485350AA25(0.42)18(0.38)RefAG25(0.42)18(0.37)1.0000.425--2.3560.001GG10(0.16)12(0.25)0.6000.213--1.6890.940.33168A75(0.62)54(0.56)RefG45(0.38)42(0.44)0.7710.446--1.3330.870.35204  rs12255372GG22(0.35)23(0.48)RefGT29(0.47)15(0.31)2.0210.860--4.7502.630.10459TT11(0.18)10(0.21)1.1500.408--3.2430.070.79157G73(0.59)61(0.64)RefT51(0.41)35(0.36)1.2180.704--2.1070.500.48137Table 6Distribution of WNT pathway gene SNPs genotype and allele frequencies in colorectal cancer cases and control population based on age (\>57).SNPVariantCases (Freq)ControlsORCIχ^2^ ValueP-Valuers7775Arg/Arg48 (0.80)40 (0.65)RefArg/Gly11 (0.18)21(0.34)0.4370.188--1.0133.820.05064Gly/Gly1 (0.02)1 (0.01)0.8330.051--13.7500.020.89844Arg107(0.89)101 (0.81)RefGly13 (0.11)23 (0.19)0.5340.256--1.1102.890.08935  rs454886TT28(0.47)29 (0.47)RefCT29 (0.48)24 (0.39)1.2510.591--2.6490.340.55739CC3 (0.05)9 (0.14)0.3450.085--1.4092.330.12679T85 (0.71)82 (0.67)RefC35 (0.29)42 (0.33)0.8040.468--1.3820.620.42925  rs459552Val/Val45 (0.76)41 (0.66)RefVal/Asp13 (0.22)21 (0.34)0.5640.251--1.2691.940.16397Asp/Asp1 (0.02)0(0.0)2.7360.108--69.0430.900.34233Val103(0.87)103(0.83)RefAsp15 (0.13)21 ()0.170.7140.349--1.4630.850.35605  rs2075241GG44 (0.75)39 (0.65)RefGC12 (0.20)21 (0.35)0.5060.221--1.1622.620.10546CC3 (0.05)00.06.2130.311--124.0552.580.10827G100(0.85)99 (0.82)RefC18 (0.15)21 (0.18)0.8490.426--1.6890.220.63980  rs2284396TT32 (0.53)26 (0.43)RefTC24 (0.40)22 (0.36)0.8860.408--1.9260.090.76063CC4 (0.07)13 (0.21)0.2500.073--0.8595.27**0.02165**T88 (0.73)74 (0.60)RefC32 (0.27)48 (0.40)0.5610.325--0.9664.39**0.03607**  rs3763511CC42 (0.70)46 (0.74)RefCT15 (0.25)16 (0.26)1.0270.453--2.3300.000.94958TT3 (0.05)0 (0.0)7.6590.384--152.6423.170.07495C99 (0.82)108(0.87)RefT21 (0.18)16 (0.13)1.4320.707--2.8991.000.31691  rs3923086TT21 (0.36)23 (0.37)RefTG30 (0.52)29 (0.47)1.1330.519--2.4750.100.75405GG7 (0.12)10 (0.16)0.7670.247--2.3800.210.64528T72 (0.62)75 (0.60)RefG44 (0.38)49 (0.40)0.9350.556--1.5730.060.80113  rs3923087AA20 (0.33)21 (0.34)RefAG24 (0.40)26 (0.42)0.9690.424--2.2150.010.94091GG16 (0.27)15 (0.24)1.1200.440--2.8480.060.81187A64 (0.53)68 (0.55)RefG56(0.47)56 (0.45)1.0620.642--1.7580.060.81350  rs4791171AA18 (0.30)21 (0.33)RefAG28 (0.47)25 (0.40)1.3070.570--2.9940.400.52679GG14 (0.23)16 (0.26)1.0210.393--2.6510.000.96622A64 (0.53)67 (0.54)RefG56 (0.47)57 (0.46)1.0290.622--1.7010.010.91284  rs4135385AA47 (0.78)41 (0.66)RefAG13 (0.22)19 (0.31)0.5970.263--1.3561.530.21550GG0 (0.0)2 (0.03)0.1750.008--3.7452.240.13485A107(0.89)101(0.81)RefG13 (0.11)23 (0.19)0.5340.256--1.1102.890.08935  rs13072632CC28 (0.47)30 (0.48)RefCT20 (0.34)26 (0.42)0.8240.379--1.7940.240.62595TT11 (0.19)6 (0.10)1.9640.641--6.0211.420.23310C76 (0.64)86 (0.69)RefT42 (0.36)38 (0.31)1.2510.731--2.1390.670.41342  rs6485350AA21 (0.36)18 (0.29)RefAG31 (0.53)32 (0.52)0.8300.373--1.8480.210.64873GG7 (0.11)12 (0.19)0.5000.162--1.5401.480.22388A73 (0.62)68 (0.55)RefG45 (0.38)56 (0.45)0.7490.448--1.2501.230.26793  rs12255372GG25 (0.43)26 (0.42)RefGT27 (0.47)31 (0.50)0.9060.426--1.9240.070.79687TT6 (0.10)5 (0.09)1.2480.338--4.6140.110.73956G77 (0.67)83 (0.67)RefT39 (0.33)41 (0.33)1.0250.599--1.7540.010.92722

4. Discussion {#s0040}
=============

The present study evaluated the association of WNT signaling pathway gene variants with colorectal cancer susceptibility in Saudi population. Three of the 13 SNPs that were examined in this study showed significant decreased risk association with colorectal cancer. Two of the three protectively associated SNPs were found to be in the intron region and only SFRP3 gene SNP rs7775 was in the exon that codes for either Arg (CGC) or Gly (GGC). We found a strong association of the β-catenin gene rs4135385 with a decreased CRC risk. It was observed that individuals carrying GG genotype have approximately 11-fold lower risk of developing colorectal cancer relative to those having AA genotype at rs4135385 of β-catenin. This is in accordance with Wang et al. who investigated the rs4135385 and identified significant association of increased gastric cancer risk in Chinese patients having AG genotype compared to those having GG genotype ([@b0075]). In our previous study as well we found significant risk association with rs4135385 in breast cancer while the other SNP rs13072632 in β-catenin was not associated ([@b0005]). Zhang et al. reported that there is no association between rs4135385 and acute leukemia ([@b0085]).

LRP6 gene SNP rs2284396 showed decreased risk of colorectal cancer in above 57 years old patients with CC genotype and C allele. A fourfold decreased risk of developing CRC was observed in individuals with CC genotype compared to those having TT genotype at rs2284396. SNP rs2284396 as well as other SNPs in LRP6 didn't show any association in diabetes mellitus in Japanese population ([@b0080]). However, Bai et al. reported an association of LRP6 SNP rs2284396 with Alzheimer\'s disease ([@b0020]).

SFRP3 gene showed significant protective association in female patients harbouring minor allele G. The G allele of rs7775 codes for Gly while the C allele codes for Arg. Women having Gly at codon 324 (rs7775) of SFRP3 have 2.5-fold lower risk of developing CRC relative to those have Arg at this locus. Our finding of the strong protection conferred by the GG genotype of rs7775 against colorectal cancers however in a small population size is significant and provides strong reason for examination of this SNP in larger studies in other ethnic groups. In our previous study we found that the CG and GG genotypes of rs7775 were protectively associated with breast cancers ([@b0005]). Our results are in contrast with the findings of [@b0070] who reported that variations in rs7775 significantly increased risk for CRC in German patients ([@b0070]). Few other studies found no association of this SNP with colorectal cancer ([@b0030]) and osteoarthritis ([@b0050]). Thus, it may be possible that rs7775 brings about different outcome in cooperation with other SNPs and warrants a detailed investigation to demonstrate its role in colorectal carcinogenesis as well as other diseases.

Significant risk association of developing colorectal cancer was not observed with 12 of the 13 SNPs examined in AXIN2, APC, SFRP3, LRP6, DKK3, DKK4, and TCF4 as well as with one of the SNPs in β-catenin gene (rs13072632) in the overall study population ([Table 2](#t0010){ref-type="table"}). Fernández-Rozadilla and colleagues examined a set of 37 SNPs in Wnt and BMP pathways different than those in our study except for rs459552 in APC and observed no association with colorectal cancer in Spanish population ([@b0040]). It may be conceived that individually these SNPs might be posing little or no risk and may be exerting its effect in combination with other genetic variants or factors. Alternatively, other SNPs in these genes or possibly other genes in the Wnt pathway may have a greater role to play in the initiation of colorectal cancers.

In the present study, we performed pathway based genetic association and identified three SNPs in critical genes in Wnt signaling to be significantly associated with reduced colorectal cancer risk. Genetic variants in SFRP3 (rs7775), β-catenin (rs4135385) and LRP6 (rs2284396) genes correlated with considerable protection against colorectal cancer in our population. Though, the sample size is small in our study, the findings are noteworthy that need to be validated in larger and ethnically diverse groups for the identified potential genetic markers to be used for colorectal cancer screening.
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